Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates-Reference-Cited by-同舟云学术

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

Published:2016-05 Issue:5 Volume:60 Page:3227-3231
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Buehrle Deanna J.¹,Shields Ryan K.²³,Chen Liang⁴,Hao Binghua³,Press Ellen G.²,Alkrouk Ammar²,Potoski Brian A.¹,Kreiswirth Barry N.⁴,Clancy Cornelius J.²³⁵,Nguyen M. Hong²³

Affiliation:

1. Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

2. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

3. XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

4. Rutgers University-New Jersey Medical School, Newark, New Jersey, USA

5. VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA

Abstract

ABSTRACT We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.

Funder

HHS | National Institutes of Health

NIH

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02969-15

Reference25 articles.

1. Prevalence of multidrug-resistant pseudomonas aeruginosa and carbapenem-resistant enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009

2. Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa